Näytä suppeat kuvailutiedot

dc.contributor.authorOlkinuora, Alisa
dc.contributor.authorMäki-Nevala, Satu
dc.contributor.authorUkwattage, Sanjeevi
dc.contributor.authorRistimäki, Ari
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorPeltomäki, Päivi
dc.date.accessioned2024-04-30T09:09:33Z
dc.date.available2024-04-30T09:09:33Z
dc.date.issued2024
dc.identifier.citationOlkinuora, A., Mäki-Nevala, S., Ukwattage, S., Ristimäki, A., Ahtiainen, M., Mecklin, J.-P., & Peltomäki, P. (2024). Novel insights into tumorigenesis revealed by molecular analysis of Lynch syndrome cases with multiple colorectal tumors. <i>Frontiers in Oncology</i>, <i>14</i>, Article 1378392. <a href="https://doi.org/10.3389/fonc.2024.1378392" target="_blank">https://doi.org/10.3389/fonc.2024.1378392</a>
dc.identifier.otherCONVID_213409193
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/94586
dc.description.abstractBackground: Lynch syndrome (LS) is an autosomal dominant multi-organ cancer syndrome with a high lifetime risk of cancer. The number of cumulative colorectal adenomas in LS does not generally exceed ten, and removal of adenomas via routine screening minimizes the cancer burden. However, abnormal phenotypes may mislead initial diagnosis and subsequently cause suboptimal treatment. Aim: Currently, there is no standard guide for the care of multiple colorectal adenomas in LS individuals. We aimed to shed insight into the molecular features and reasons for multiplicity of adenomas in LS patients. Methods: We applied whole exome sequencing on nine adenomas (ten samples) and three assumed primary carcinomas (five samples) of an LS patient developing the tumors during a 21-year follow-up period. We compared the findings to the tumor profiles of two additional LS cases ascertained through colorectal tumor multiplicity, as well as to ten adenomas and 15 carcinomas from 23 unrelated LS patients with no elevated adenoma burden from the same population. As LS associated cancers can arise via several molecular pathways, we also profiled the tumors for CpG Island Methylator Phenotype (CIMP), and LINE-1 methylation. Results: All tumors were microsatellite unstable (MSI), and MSI was present in several samples derived from normal mucosa as well. Interestingly, frequent frameshift variants in RNF43 were shared among substantial number of the tumors of our primary case and the tumors of LS cases with multiple tumors but almost absent in our control LS cases. The RNF43 variants were completely absent in the normal tissue, indicating tumor-associated mutational hotspots. The RNF43 status correlated with the mutational signature SBS96. Contrary to LS tumors from the reference set with no elevated colorectal tumor burden, the somatic variants occurred significantly more frequently at C>T in the CpG context, irrespective of CIMP or LINE-1 status, potentially indicating other, yet unknown methylation-related mechanisms. There were no signs of somatic mosaicism affecting the MMR genes. Somatic variants in APC and CTNNB1 were unique to each tumor. Conclusion: Frequent somatic RNF43 hot spot variants combined with SBS96 signature and increased tendency to DNA methylation may contribute to tumor multiplicity in LS.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherFrontiers Media SA
dc.relation.ispartofseriesFrontiers in Oncology
dc.rightsCC BY 4.0
dc.subject.otherLynch syndrome
dc.subject.otherexome sequencing
dc.subject.otherpanel sequencing
dc.subject.othermultiple adenomas
dc.titleNovel insights into tumorigenesis revealed by molecular analysis of Lynch syndrome cases with multiple colorectal tumors
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202404303214
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2234-943X
dc.relation.volume14
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 Olkinuora, Mäki-Nevala, Ukwattage, Ristimäki, Ahtiainen, Mecklin and Peltomäki.
dc.rights.accesslevelopenAccessfi
dc.subject.ysokasvaimet
dc.subject.ysoLynchin oireyhtymä
dc.subject.ysoeksomisekvensointi
dc.subject.ysosuolistosyövät
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p2299
jyx.subject.urihttp://www.yso.fi/onto/yso/p23697
jyx.subject.urihttp://www.yso.fi/onto/yso/p39097
jyx.subject.urihttp://www.yso.fi/onto/yso/p25845
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.3389/fonc.2024.1378392
jyx.fundinginformationThe author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from Biomedicum Helsinki Foundation (to AO); the Jane and Aatos Erkko Foundation (to PP); the Academy of Finland (grant number 330606 to PP, and 331284 to SM-N); Cancer Foundation Finland sr (to AO, PP, and AR); the Finska Läkaresällskapet (to AR); Medicinska Understödsföreningen Liv & Hälsa (to AR); Helsinki University Central Hospital Research Funds (to AR); and the Sigrid Juselius Foundation (to PP and AR).
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0